Dallas, TX -- (SBWIRE) -- 05/05/2010 -- ReportsandReports Announce it Will Carry the Liver Cancer - Drug Pipeline Analysis and Market Forecasts to 2016 Market Research Report in its Store.

Browse the complete Report on: http://www.reportsandreports.com/market-reports/liver-cancer-drug-pipeline-analysis-and-market-forecasts-to-201/

GlobalData, the industry analysis specialist’s new report, “Liver Cancer - Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global liver cancer market. The report identifies the key trends shaping and driving the global liver cancer market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global liver cancer sector.

GlobalData analyzed that the liver cancer market has high unmet needs in terms of both efficacy and safety. More than 90% of patients diagnosed with liver cancer are between 45 years and 85 years of age. Nexavar is the only available Food and Drug Association (FDA) approved treatment for advanced liver cancer patients. However, the median survival time in patients treated with Nexavar is only three months more than for patients treated with placebo. Moreover, Nexavar has a low safety profile. About 39% and 6% of Nexavar-treated patients reported grade 3 and grade 4 adverse reactions respectively. Therefore, the unmet need in the liver cancer market was valued at 56%. This is expected to decrease significantly between 2009 and 2016 due to the expected launch of many first-in-class and me-too drugs. The majority of the first-in-class drugs are for the early stages of liver cancer and therefore they are expected to treat patients for whom no treatment options currently exist.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:

• Annualized global liver cancer market revenues data from 2001 to 2009, forecast forward for seven years to 2016.

• Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan.

• Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The first-in-class molecules are primarily Tumor Necrosis Factor Alpha (TNF-alpha) inhibitors, selective estrogen receptor modulators and light activated therapies.

• Analysis of the current and future market competition in the global liver cancer market. Key future market players covered are Bristol-Myers Squibb, Pfizer Inc., F.Hoffmann-La Roche, Bayer Ag, Onyx Pharmaceuticals, Kowa Pharmaceuticals and Celsion Corporation.

• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

• Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for future market associated with the liver cancer market.
Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

• Develop business strategies by understanding the trends shaping and driving the global liver cancer market.

• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global liver cancer market in future.

• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

• What’s the next big thing in the global liver cancer market landscape? – Identify, understand and capitalize.

1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Liver Cancer Market: Market Characterization 6
2.1 Overview 6
2.2 Liver Cancer Market Size 6
2.3 Liver Cancer Market Forecast and CAGR 7
2.4 Drivers and Barriers for Liver Cancer Market 7
2.4.1 Drivers for Liver Cancer Market 7
2.4.2 Restraints for Liver Cancer Market 8
2.5 Opportunity and Unmet Need 9
2.5.1 Impact Analysis of Unmet Needs 10
2.6 Key Takeaway 10
3 Liver Cancer Market: Competitive Assessment 11
3.1 Overview 11
3.2 Strategic Competitor Assessment 11
3.3 Product Profile for the Major Marketed Products in the Liver Cancer Market 12
3.3.1 Nexavar (sorafenib) 12
3.3.2 Miripla 14
3.3.3 Cisplatin 14
3.3.4 Cisplatin/doxorubicin 15
3.3.5 Cisplatin/vincristine/fluorouracil 16
3.4 Key Takeaway 17
4 Liver Cancer Market: Pipeline Assessment 19
4.1 Overview 19
4.2 Strategic Pipeline Assessment 19
4.2.1 Technology Trends Analytic Framework 19
4.3 Liver Cancer – Promising Drugs under Clinical Development 21
4.4 Molecule Profile for Promising Drugs under Clinical Development 21
4.4.1 Brivanib 21
4.4.2 ThermoDox 23
4.5 Liver Cancer Market – Clinical Pipeline by Mechanism of Action 24
4.6 Liver Cancer Pipeline – Pipeline by Clinical Phases of Development 25
4.6.1 Liver Cancer – Regulatory Filing and Phase III Clinical Pipeline 25
4.6.2 Liver Cancer – Phase II Clinical Pipeline 26
4.6.3 Liver Cancer – Phase I Clinical Pipeline 30
4.6.4 Liver Cancer – Preclinical Pipeline 32
4.6.5 Liver Cancer – Discovery Pipeline 33
4.7 Key Takeaway 33
5 Liver Cancer Market: Implications for Future Market Competition 34
6 Liver Cancer Market: Future Players in Liver Cancer Market 36
6.1 Introduction 36
6.2 Bristol-Myers Squibb Company 36
6.2.1 Company Overview 36
6.2.2 Business Description 37
6.2.3 Pipeline 38
6.3 Pfizer Inc. 39
6.3.1 Company Overview 39
6.3.2 Business Description 39
6.3.3 Pipeline 41
6.4 F. Hoffmann-La Roche 42
6.4.1 Company Overview 42
6.4.2 Business Description 42
6.4.3 Pipeline 44
6.5 Bayer AG 45
6.5.1 Company Overview 45
6.5.2 Pipeline 47
6.6 Onyx Pharmaceuticals, Inc. 47
6.6.1 Company Overview 47
6.6.2 Business Description 47
6.6.3 Pipeline 48
6.7 Kowa Pharmaceuticals America, Inc. 48
6.7.1 Company Overview 48
6.7.2 Pipeline 49
6.8 Celsion Corporation 49
6.8.1 Company Overview 49
6.8.2 Business Description 49
6.8.3 Pipeline 50
7 Liver Cancer Market: Appendix 51
7.1 Definitions 51
7.2 Acronyms 51
7.3 Research Methodology 52
7.3.1 Coverage 53
7.3.2 Secondary Research 53
7.3.3 Forecasting 53
7.3.4 Primary Research 55
7.3.5 Expert Panel validation 56
7.4 Contact Us 56
7.5 Disclaimer 56
7.6 Sources 56

Related Reports

http://www.reportsandreports.com/market-reports/cancer-liver-cancer-therapy-area-pipeline-report/
http://www.reportsandreports.com/market-reports/pipeline-insight-small-molecule-targeted-cancer-therapies-new-/
http://www.reportsandreports.com/market-reports/worldwide-market-for-cancer-diagnostics-4th-edition-the/

About ReportsandReports
ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
http://www.reportsandreports.com/
Visit our Blog: http://reportsnreports.wordpress.com/